Kristen Ciombor, MD
Enriched profileAssociate Professor of Medicine, Division of Hematology and Oncology; Ingram Associate Professor of Cancer Research · Vanderbilt University Medical Center
Kristen Ciombor is Associate Professor of Medicine, Division of Hematology and Oncology; Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center. OpenAlex indexes 196 publications with 14,826 citations (h-index 30); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.
Data verified 10 Oct 2026
Overview
Updated 14 Oct 2026
Kristen Ciombor, MD, is Associate Professor of Medicine, Division of Hematology and Oncology at Vanderbilt University Medical Center (Vanderbilt-Ingram Cancer Center). The public record shows 196 publications with 14,826 citations (h-index 30), centered on Colorectal Cancer Treatments and Studies, Colorectal Cancer Surgical Treatments, Pancreatic and Hepatic Oncology Research. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 14 companies, 3 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Colorectal Cancer Treatments and Studies
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 52.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
Sponsor: National Cancer Institute (NCI)
- Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Sponsor: Academic and Community Cancer Research United
Industry payments
Updated 14 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Exelixis Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
43.9%Serotonin-3 Receptor Antagonist30.6%Ondansetron Hcl53%Ondansetron Odt47%Part D<11 patientsAntidiarrheal microorganisms13.3%Creon100%Part D<11 patientsNervous system
28.6%Gabapentinoids15.3%Gabapentin100%Part D<11 patientsPhenothiazine13.3%Prochlorperazine Maleate100%Part D≥11 patientsBlood & clotting
15.3%Factor Xa inhibitor15.3%Xarelto100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
3 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Vanderbilt Network Lead Academic Participating Site for the NCTN
Vanderbilt University Medical Center
FY2026$367,000UG1CA233270 - Gastrointestinal Cancer Research Program
Vanderbilt University Medical Center
FY2026$84,345P30CA068485 - Vanderbilt Network Lead Academic Participating Site for the NCTN
Vanderbilt University Medical Center
FY2025$438,545UG1CA233270
Congress activity
Updated 14 Oct 2026
60 congress contributions (2012–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Access to fertility preservation services among commercially insured adults with early-onset colorectal cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
Journal of clinical oncology
Clinical Trial2026 - Immunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?
Journal of clinical oncology
Comment2023 - BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape.
Journal of clinical oncology
Article2022
Most-cited works
by citation count (OpenAlex)- 01Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeArticle6,616 citations2017
- 02Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyArticle1,706 citations2021
- 03NCCN Guidelines Insights: Colon Cancer, Version 2.2018Article995 citations2018
- 04Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced CholangiocarcinomaArticle698 citations2017
- 05Treatment of Metastatic Colorectal Cancer: ASCO GuidelineArticle661 citations2022
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
onclive.com/authors/kristen-ciombor-md-msci
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.vumc.org ↗
Editorial & leadership roles
journal and society appointments- Chair
Colorectal/Anal Working Group, Eastern Cooperative Oncology Group (ECOG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗ - Member
NCCN Colorectal Guidelines Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗ - Member
NCI Gastrointestinal Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
Secondary affiliations
appointments beyond the home institution- Co-Leader
Gastrointestinal Cancer Research Program, Vanderbilt-Ingram Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center
Brian Rini, MD
Vanderbilt University Medical Center
William Schaffner, MD
Vanderbilt University Medical Center
Jordan Berlin, MD
Vanderbilt University Medical Center
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH